Cinco prateleiras. Cada análise cabe numa.

The most-studied research peptide in rodents. Human evidence remains thin and the FDA narrowed its compounding pathway in 2023.

The actin-binding biology is real; what most online sources sell as TB-500 is a fragment, not the full thymosin beta-4 protein.

The cleanest evidence file in the database, peer-reviewed cosmetic and wound work, plus topical formulations available outside the research channel.

Mitochondrial-derived 16-aa peptide with a coherent metabolic-signalling mechanism. Human evidence remains limited to small early-phase pilots.

Long-acting GHRH analogue. Strong mechanism, defined PK profile, very limited published human evidence beyond Phase 1.

Selective ghrelin receptor agonist with cleaner GH-release profile than older GHRPs. Phase 2 in postoperative ileus failed; remains a research-channel-only peptide.

FDA-approved GHRH analogue for HIV-associated lipodystrophy. The most-developed peptide in the GHRH/GHRP class with a regulated indication.

29-amino-acid GHRH fragment; previously FDA-approved for paediatric GH deficiency (Geref, withdrawn 2008). Now a compounding-pharmacy product without a current FDA-approved label.